Exelixis, Inc. 10-Q Summary: Quarter Ended June 30, 2001
Business Context and Reporting Period
Exelixis, Inc. is a genomics-based biotechnology company focused on product development through comparative genomics and model system genetics. The company operates an internal cancer discovery program and maintains active partnerships with major pharmaceutical and agricultural firms, including Aventis, Bayer, Bristol-Myers Squibb, and Protein Design Labs. This report covers the quarterly period ended June 30, 2001.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $16.3 million | $11.6 million |
| Net Loss | $(36.4) million | $(18.3) million |
| Net Loss Per Share (Basic/Diluted) | $(0.81) | $(0.90) |
| Operating Cash Flow | $(15.4) million (Used) | $3.4 million (Provided) |
| Cash and Short-Term Investments | $123.1 million | $N/A (IPO proceeds raised in 2000) |
| Total Debt (Notes, Leases, Convertible) | $49.2 million | $7.0 million |
| Accumulated Deficit | $(166.5) million | $(130.0) million |
Material Changes vs. Prior Period
- Revenue Growth: Revenues increased 41% year-over-year to $16.3 million, driven by new collaborations (Protein Design Labs, Bristol-Myers Squibb) and the acquisition of Artemis Pharmaceuticals.
- Increased Expenses: Operating expenses rose to $55.6 million from $31.5 million. This includes a $6.7 million charge for acquired in-process research and development (IPR&D) from the Artemis acquisition and $2.3 million in goodwill amortization.
- Debt Expansion: The company issued a $30.0 million convertible promissory note to Protein Design Labs in May 2001, significantly increasing liabilities compared to the prior period.
- Cash Flow Shift: Operating activities consumed $15.4 million in cash, reversing the positive operating cash flow of $3.4 million seen in the prior year, primarily due to funding net operating losses.
Outlook, Risks, and Unusual Items
- Acquisitions: In May 2001, Exelixis acquired Artemis Pharmaceuticals GmbH for approximately $22.3 million (stock and options). This resulted in a $6.7 million immediate expense for IPR&D.
- New Collaborations:
- Protein Design Labs (PDL): Agreed to provide $4.0 million annual research funding and purchased a $30.0 million convertible note.
- Bristol-Myers Squibb (BMS): Entered a collaboration in July 2001 involving a $20.0 million stock purchase, a $5.0 million upfront license fee, and $3.0 million annual research funding. Exelixis also received an exclusive license to a cancer compound (Rebeccamycin analogue).
- Pharmacia Reacquisition: Exelixis announced the reacquisition of rights to metabolism and Alzheimer's research programs from Pharmacia, effective February 2002. This terminates approximately $9.0 million in annual funding previously expected from Pharmacia.
- Liquidity: Management believes current cash, investments, and committed funding are sufficient for at least two years. However, the company filed a Form S-3 to offer up to $150.0 million of common stock to raise additional capital.
- Risks: The company has a history of net losses and expects to continue incurring losses. Key risks include the failure to achieve milestones in collaborations, the inability to commercialize the Rebeccamycin compound, and the need for future capital raises which may be dilutive.
Investor Verification Checklist
- Verify the sustainability of revenue streams following the termination of the Pharmacia funding ($9.0 million annual loss).
- Assess the timeline and regulatory risks associated with the newly acquired Rebeccamycin analogue from Bristol-Myers Squibb.
- Monitor the dilution impact of the $30.0 million convertible note to Protein Design Labs and potential future equity offerings.
- Review the integration progress and financial performance of the Artemis Pharmaceuticals acquisition.
- Confirm the company's ability to meet financial covenants on its $12.0 million equipment lease line of credit.